Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib
These results illustrate that CSRP2 regulates the tumor microenvironment to promote HCC growth and drive lenvatinib tolerance via the CSRP2/ATF2/CCL28 axis. Targeting this pathway could synergize with lenvatinib to treat HCC more effectively.
Authors
- Zehuan Li (ORCID: https://orcid.org/0000-0001-8084-7428)
- Xiaowu Huang (ORCID: https://orcid.org/0000-0002-9035-6056)
- Sheng Su (ORCID: https://orcid.org/0000-0003-3523-8222)
- Jia Li (ORCID: https://orcid.org/0000-0002-3606-3949)
- Songyang Yu (ORCID: https://orcid.org/0009-0004-0775-3926)
- Pengcheng Wang (ORCID: https://orcid.org/0000-0002-1658-3138)
- Yu Gong (ORCID: https://orcid.org/0000-0001-7800-5918)
- Zhiqiang Hu (ORCID: https://orcid.org/0000-0002-8842-6035)
- Xinming Ye (ORCID: https://orcid.org/0000-0002-5971-8741)
- C Chen (ORCID: https://orcid.org/0000-0001-5396-3204)
Institutions
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012201
- Citations
- 2
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.59